Atlas Trials

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Clinical trial NCT03924245 · TERMINATED

Trial details

NCT number
NCT03924245
Sponsor
Vanderbilt-Ingram Cancer Center
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Fallopian Tube CancerFallopian Tube CarcinosarcomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaHigh Grade Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaOvarian CarcinosarcomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaPrimary Peritoneal Serous AdenocarcinomaRecurrent Endometrial CarcinomaRecurrent Ovarian Carcinoma
Start date
2020-10-01
Primary completion
2022-02-04
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.